iTeos Therapeutics to Present at Piper Jaffray 31st Annual Healthcare Conference

iTeos Therapeutics to Present at Piper Jaffray 31st Annual Healthcare Conference

Corporate
Cambridge, MA  and Gosselies, Belgium – November 26, 2019 – iTeos Therapeutics SA, a privately-held biotechnology company developing novel cancer immunotherapies, today announced that Michel Detheux, Ph.D., President and Chief Executive Officer, will present at the upcoming Piper Jaffray 31st…
Read more

Previous news

  • iTeos Therapeutics to Participate in Upcoming U.S. Conferences in September
    Corporate

    iTeos Therapeutics to Participate in Upcoming U.S. Conferences in September

    Gosselies, Belgium – August 29, 2018 – iTeos Therapeutics SA, a biotechnology company developing novel cancer immunotherapies, today announced that Michel Detheux, Ph.D., Chief Executive Officer of iTeos, will present in two upcoming U.S. conferences in September.  Citi’s 13th Annual Biotech Conference on Wednesday, September 5, 2018 at 11:15 a.m. ET in Boston, MA. Wells Fargo Securities 2018 Healthcare Conference on Thursday, September 6, 2018 at 3:40 p.m. ET in Boston, MA.   About iTeos Therapeutics  iTeos Therapeutics is a privately-held, clinical-stage biopharmaceutical company dedicated to extending and improving the lives of cancer patients by designing and developing next generation immunotherapies. The Company is advancing EOS100850, an insurmountable and non-brain penetrant adenosine A2A receptor antagonist, into a Phase I trial in the second half of 2018. A second program for its human ADCC-enabling anti-TIGIT antibody (EOS884448) is expected to enter the clinic in 2019. Based in Gosselies, Belgium and Cambridge, MA, iTeos Therapeutics was founded out of the Ludwig Institute for Cancer Research (LICR) and the de Duve Institute (Université Catholique de Louvain) in 2011. In June 2018, the Company completed a $75 million (€64 million) Series B financing led by MPM Capital, alongside new investors HBM Partners, 6 Dimensions Capital and Curative Ventures. All previous investors including Fund +, VIVES II and SRIW, as well as SFPI, also participated in this funding round.For more information, please visit www.iteostherapeutics.com. For further information, please contact: Michel Detheux, CEO iTeos Therapeutics info@iteostherapeutics.com   Amber Fennell, Mathew Neal, Sukaina Virji, Hendrik Thys Consilium Strategic Communications +44 203 709 5700 iteos@consilium-comms.com   Sarah McCabe and Carl Mauch Stern Investor Relations, Inc. + 1 212 362 1200 iteos@sternir.com

  • iTeos Therapeutics to Participate in Upcoming U.S. Conferences in August
    Corporate

    iTeos Therapeutics to Participate in Upcoming U.S. Conferences in August

    Gosselies, Belgium – August 6, 2018 – iTeos Therapeutics SA, a biotechnology company developing novel cancer immunotherapies, today announced that management will participate in two upcoming U.S. conferences in August.  Managementwill be available for one-on-one meetings at the Oppenheimer Newport Summit for Revolutionary Biotechnology, on Monday, August 13, 2018 in Newport, Rhode Island. Michel Detheux, Ph.D., Chief Executive Officer of iTeos, will present a company overview at the 2018 Wedbush PacGrow Healthcare Conference on Tuesday, August 14, 2018 at 1:20 p.m. ET in New York, NY.     About iTeos Therapeutics  iTeos Therapeutics is a privately-held, clinical-stage biopharmaceutical company dedicated to extending and improving the lives of cancer patients by designing and developing next generation immunotherapies. The Company is advancing EOS100850, an insurmountable and non-brain penetrant adenosine A2A receptor antagonist, into a Phase I trial in the second half of 2018. A second program for its human ADCC-enabling anti-TIGIT antibody (EOS884448) is expected to enter the clinic in 2019. Based in Gosselies, Belgium and Cambridge, MA, iTeos Therapeutics was founded out of the Ludwig Institute for Cancer Research (LICR) and the de Duve Institute (Université Catholique de Louvain) in 2011. In June 2018, the Company completed a $75 million (€64 million) Series B financing led by MPM Capital, alongside new investors HBM Partners, 6 Dimensions Capital and Curative Ventures. All previous investors including Fund +, VIVES II and SRIW, as well as SFPI, also participated in this funding round.For more information, please visit www.iteostherapeutics.com.   For further information, please contact: Michel Detheux, CEO iTeos Therapeutics info@iteostherapeutics.com   Amber Fennell, Mathew Neal, Sukaina Virji, Hendrik Thys Consilium Strategic Communications +44 203 709 5700 iteos@consilium-comms.com   Sarah McCabe and Carl Mauch Stern Investor Relations, Inc. + 1 212 362 1200 iTeos@sternir.com

  • iTeos Therapeutics Appoints Scott Chappel as Chief Scientific Officer
    Corporate

    iTeos Therapeutics Appoints Scott Chappel as Chief Scientific Officer

    Gosselies, Belgium – July 3, 2018 – iTeos Therapeutics SA, a biotechnology company developing novel cancer immunotherapies, today announced the appointment of Scott Chappel, Ph.D., as its Chief Scientific Officer (CSO). Reporting to Chief Executive Officer Michel Detheux, Ph.D., Dr. Chappel will be responsible for expanding the pipeline and leading the preclinical development of the Company’s best-in-class immuno-oncology programs that target the tumor microenvironment to improve the outcomes for cancer patients.  “We are delighted that Scott has joined iTeos as CSO. He has been a leader in the life sciences sector for more than three decades and is an accomplished scientist who has directed research that has led to the development of several FDA-approved and marketed biological products,” commented Michel Detheux, Ph.D., Chief Executive Officer of iTeos. “His experience will be invaluable to the next phase of our growth as we build an attractive pipeline and transition our programs into the clinic.” With significant biotech experience and a strong scientific research and drug development track record, Dr. Chappel has founded and held several senior leadership roles in companies developing oncology and other novel therapies. Prior to joining iTeos, he was a founder and Chief Technology Officer at Surface Oncology, where he oversaw all antibody generation, engineering, production and characterization as well as all preclinical IND-enabling studies and GMP manufacturing of antibodies. He was also a founder and Chief Scientific Officer at Arteaus Therapeutics (acquired by Eli Lilly in 2014) and Tokai Pharmaceuticals, where he worked to develop an oral therapeutic for the treatment of prostate cancer. Prior to Tokai, he held roles as a Senior Vice President of Research at Dyax and as a Chief Scientist at Serono.  “I am thrilled to join iTeos as CSO and look forward to working with Michel and the team to rapidly advance the Company’s pipeline of high-value, immuno-oncology programs targeting the tumor microenvironment,” added Scott Chappel, Ph.D, Chief Scientific Officer of iTeos. “I am also very excited about the potential therapeutic benefits of EOS100850, an adenosine A2A antagonist, and EOS884448, an anti-TIGIT antibody, which we expect to move into the clinic within 12 months.” About iTeos Therapeutics  iTeos Therapeutics is a privately-held, clinical-stage biopharmaceutical company dedicated to extending and improving the lives of cancer patients by designing and developing next generation immunotherapies. The Company is advancing EOS100850, an insurmountable and non-brain penetrant adenosine A2A receptor antagonist, into a Phase I trial in the second half of 2018. A second program for its human ADCC-enabling anti-TIGIT antibody (EOS884448) is expected to enter the clinic in 2019. Based in Gosselies, Belgium and Cambridge, MA, iTeos Therapeutics was founded out of the Ludwig Institute for Cancer Research (LICR) and the de Duve Institute (Université Catholique de Louvain) in 2011. In June 2018, the Company completed a $75 million (€64 million) Series B financing led by MPM Capital, alongside new investors HBM Partners, 6 Dimensions Capital and Curative Ventures. All previous investors including Fund +, VIVES II and SRIW, as well as SFPI, also participated in this funding round. For more information, please visit www.iteostherapeutics.com. For further information, please contact: Michel Detheux, CEO iTeos Therapeutics info@iteostherapeutics.com   Amber Fennell, Mathew Neal, Sukaina Virji, Hendrik Thys Consilium Strategic Communications +44 203 709 5700 iteos@consilium-comms.com   Sarah McCabe Stern Investor Relations, Inc. + 1 212 362 1200 sarah@sternir.com  

  • iTeos Therapeutics Expands Board of Directors with the Appointment of David Hallal as Chairman and Tim Van Hauwermeiren as an Independent Director
    Corporate

    iTeos Therapeutics Expands Board of Directors with the Appointment of David Hallal as Chairman and Tim Van Hauwermeiren as an Independent Director

    - Two new appointments follow oversubscribed $75 million (€64 million) Series B financing and support next stage of iTeos’ growth Gosselies, Belgium – June 27, 2018 – iTeos Therapeutics SA, a biotechnology company developing novel cancer immunotherapies, today announced the appointment of David Hallal,  former Chief Executive Officer of Alexion Pharmaceuticals, and Tim Van Hauwermeiren, Chief Executive Officer of argenx, to its board of directors. David has been appointed Chairman and Tim joins as an independent non-executive director.  “David and Tim are both extremely well regarded executives and we are thrilled to have them join the iTeos Board at this stage in our growth. Their combined commercial experience running large biotechnology companies will be invaluable as we advance our innovative next-generation immuno-oncology pipeline and expand our presence in the U.S.,” said Michel Detheux, Ph.D., Chief Executive Officer of iTeos. “Our recent financing and diversified Board put us in an even stronger position to rapidly move our promising therapies into the clinic and to design additional therapeutic candidates based on our industry-leading drug discovery and early clinical development expertise.” David Hallal brings nearly 30 years of senior executive leadership experience in growing and operating several of the world’s most successful biotechnology companies. David spent more than 10 years at Alexion Pharmaceuticals as Chief Executive Officer, Chief Operating Officer and Chief Commercial Officer and played a central role in transforming the company from a development-stage company in 2006 to a commercial-stage company operating in more than 50 countries with three approved products and more than $3 billion in annual revenues by 2016. Prior to Alexion, David held leadership positions at Amgen, Biogen and Eyetech. He also serves as Chairman of Scholar Rock (Nasdaq: SRRK).  Tim Van Hauwermeiren is currently Chief Executive Officer of argenx (Euronext & Nasdaq: ARGX), which he co-founded in 2008 and where he has also served on the Board since July 2014. At argenx, Tim has created a multi-billion-dollar enterprise with three therapies in mid- to late-stage development. Tim has more than 20 years of general management and business development experience across the life sciences and consumer goods sectors. Previously, he held senior leadership roles at Ablynx and Procter & Gamble.  “It’s an exciting time of growth and expansion at iTeos as it prepares to transition its highly differentiated adenosine A2A receptor antagonistinto the clinic, and I am delighted to join the Board as Chairman,” said David Hallal. “Together with Michel, Tim and the other Board members, I will be focused on executing the Company’s strategy to develop innovative therapies that can transform the lives of patients suffering with cancer.” “iTeos is proving to be a key player in the emerging cancer immunotherapy space and I am very much looking forward to working with the team to progress iTeos’ pipeline and provide guidance to help the Company realize its full potential,” added Tim Van Hauwermeiren. iTeos’ Board of Directors now consists of David Hallal (Chairman); Ansbert Gadicke, M.D.; Christiana Bardon M.D. MBA; Priyanka Belawat, Ph.D.; Tim Van Hauwermeiren, MSc, EMBA; Chris Buyse, MBA, Jonathan Skipper, Ph.D. and Michel Detheux, Ph.D. (CEO). About iTeos Therapeutics  iTeos Therapeutics is a privately-held, clinical-stage biopharmaceutical company dedicated to extending and improving the lives of cancer patients by designing and developing next generation immunotherapies. The Company is advancing EOS100850, an insurmountable and non-brain penetrant adenosine A2A receptor antagonist, into a Phase I trial in the second half of 2018. A second program for its human ADCC-enabling anti-TIGIT antibody (EOS884448) is expected to enter the clinic in 2019. Based in Gosselies, Belgium and Cambridge, MA, iTeos Therapeutics was founded out of the Ludwig Institute for Cancer Research (LICR) and the de Duve Institute (Université Catholique de Louvain) in 2011. In June 2018, the Company completed an oversubscribed $75 million (€64 million) Series B financing led by MPM Capital, alongside new investors HBM Partners, 6 Dimensions Capital and Curative Ventures. All previous investors including Fund +, VIVES II and SRIW, as well as SFPI, also participated in this funding round.For more information, please visit www.iteostherapeutics.com.   For further information, please contact: Michel Detheux, CEO iTeos Therapeutics info@iteostherapeutics.com   Amber Fennell, Mathew Neal, Sukaina Virji, Hendrik Thys Consilium Strategic Communications +44 203 709 5700 iteos@consilium-comms.com   Sarah McCabe Stern Investor Relations, Inc. + 1 212 362 1200 sarah@sternir.com

  • iTeos Therapeutics Completes $75 Million Series B Financing
    Financial

    iTeos Therapeutics Completes $75 Million Series B Financing

    - Oversubscribed financing round led by new U.S. investor MPM Capital  - Proceeds to support accelerated development of innovative next-generation immuno-oncology pipeline into the clinic and the company’s expansion into the U.S.    Gosselies, Belgium – June 20, 2018 – iTeos Therapeutics SA, a biotechnology company developing novel cancer immunotherapies, today announced the completion of an oversubscribed $75 million (€64 million) Series B financing led by MPM Capital, with participation from additional new investors HBM Partners, 6 Dimensions Capital and Curative Ventures. All existing investors also participated in this financing round including Fund +, VIVES II and SRIW, as well as SFPI. “This oversubscribed financing underscores the enormous potential of our innovative next-generation immuno-oncology pipelineand confirms the confidence in ourleadership team to deliver value for patients and investors. We plan to continue to rapidly advance our promising therapies into the clinic and to design additional therapeutic candidates based on our industry leading drug discovery and early clinical development expertise,” said Michel Detheux, Ph.D., Chief Executive Officer of iTeos.“We are grateful for the continued support of our existing investors and look forward to welcoming the new investors who participated in this Series B financing. We are confident their guidance will prove invaluable as we continue our growth.” Proceeds from this financing will support the advancement of several promising best-in-class immuno-oncology programs within iTeos’ unique pipeline into the clinic. This financing will also support the company’s expansion into its new U.S.-based offices in Cambridge, Massachusetts. Specifically, the funding will enable iTeos to move EOS100850, an adenosine A2Aantagonist, into the clinic in 2018 and toward clinical proof-of-concept, and EOS884448, an anti-TIGIT antibody, into the clinic in 2019. The Company’s development pipeline also includes additional drug candidates targeting the tumor microenvironment.  “We believe iTeos is a strong investment opportunity with several promising immuno-oncology drugs in its pipeline that have significant clinical advantages over competitive drug candidates,”said Dr. Gadicke, Co-founder and Managing Director of MPM. “Michel and his team have an excellent track record of discovering new ways to fight cancer and strategically growing the operations. MPM is very excited to be involved as the company expands into the U.S. and continues its evolution.” Ansbert Gadicke, M.D., Co-founder and Managing Director of MPM; Christiana Bardon M.D., Managing Director of the UBS Oncology Impact Fund managed by MPM; and Priyanka Belawat, Ph.D. Investment Advisor at HBM Partners will join the iTeos Board of Directors.  About iTeos Therapeutics  iTeos Therapeutics is a privately-held, clinical-stage biopharmaceutical company dedicated to extending and improving the lives of cancer patients by designing and developing next generation immunotherapies. The Company is advancing EOS100850, an insurmountable and non-brain penetrant adenosine A2A receptor antagonist, into a Phase I trial in the second half of 2018. A second program for its human ADCC-enabling anti-TIGIT antibody (EOS884448) is expected to enter the clinic in 2019. Based in Gosselies, Belgium, iTeos Therapeutics was founded out of the Ludwig Institute for Cancer Research (LICR) and the de Duve Institute (Université Catholique de Louvain) in 2011, with funds from the LICR, Fund+, VIVES II-Louvain Technology Fund, private investors and the Walloon Region of Belgium and the European Fund for Economic and Regional Development (FEDER). For more information, please visit www.iteostherapeutics.com. About MPM Capital MPM Capital is a venture firm founding and investing in early-stage life sciences companies that seek to cure major diseases by translating scientific innovations into positive clinical outcomes. MPM’s portfolio of companies aims to revolutionize the face of medicine across multiple areas including cancer, neuroscience, metabolic disorders and regenerative medicine. With its experienced and dedicated investment team, executive partners and entrepreneurs and its medical and scientific advisory board, MPM is powering novel medical breakthroughs that transform patients’ lives. MPM is investing in iTeos from its BV2014 and BV2018 funds as well as the UBS Oncology Impact Fund managed by MPM, which invests in both public and private equities. For more information, please visit www.mpmcapital.com. For further information, please contact: Michel Detheux, CEO iTeos Therapeutics info@iteostherapeutics.com   Amber Fennell, Mathew Neal, Sukaina Virji, Hendrik Thys Consilium Strategic Communications +44 203 709 5700 iteos@consilium-comms.com   Sarah McCabe Stern Investor Relations, Inc. + 1 212 362 1200 sarah@sternir.com   Liz Doherty MPM Capital +1 617 425 9275 ldoherty@mpmcapital.com  

  • iTeos Therapeutics to Present Preclinical Data from A2A Receptor Antagonist and Anti-TIGIT Antibody Programs at AACR
    A2a Inhibitor TIGIT

    iTeos Therapeutics to Present Preclinical Data from A2A Receptor Antagonist and Anti-TIGIT Antibody Programs at AACR

    Gosselies, Belgium– April 12, 2018 –iTeos Therapeutics SA, a biotechnology company developing novel cancer immunotherapies, today announced that it will present data for its A2Aantagonist and anti-TIGIT antibody programs in two abstracts at the upcoming American Association for Cancer Research (AACR) Annual Meeting, taking place from April 14-18, 2018 in Chicago, IL. “We continue to make good progress advancing our best-in-class A2A receptor antagonist and our promising anti-TIGIT antibody toward the clinic and are delighted to present this data at AACR,” said Michel Detheux, Ph.D., Chief Executive Officer of iTeos.“After the advancement of the A2Areceptor antagonist program into the clinic in 2018, the anti-TIGIT antibody will follow in 2019, fortifying our position as a leading player in the immunotherapy field.” Adenosine A2AReceptor Inhibitor (EOS100850): Best-in-class A2Areceptor antagonistprogram currently being evaluated for safety and efficacy in preclinical models with a Phase I trial expected to begin in 2018. Presentation Title: EOS100850, an insurmountable and non-brain penetrant A2Areceptor antagonist, inhibits adenosine-mediated T cell suppression, demonstrates anti-tumor activity and exhibits best-in class characteristics Session Title:Late-Breaking Research: Immunology 2 Session Date and Time:Tuesday, April 17, 2018 from 1:00 PM - 5:00 PM CT Session Location: Poster Section 44 Human Anti-TIGIT Antibody (EOS884448): Antagonist antibody against human TIGIT that demonstrates a classical human IgG pharmacokinetics profile. It is currently being evaluated for safety and efficacy in preclinical models with a Phase I trial expected to begin in 2019. Presentation Title: A TIGIT antagonist antibody EOS884448 shows dual mechanism of action by restoration of T cell effector functions and preferential depletion of Treg Session Title:Late-Breaking Research: Immunology 1 Session Date and Time:Monday, April 16, 2018 from 8:00 AM - 12:00 PM CT Session Location:Poster Section 45 About iTeos’ Adenosine A2AReceptor Inhibitor (EOS100850) The adenosine A2Areceptor is the main adenosine receptor expressed on immune cells, which promotes immune suppression, leading to tumor evasion. iTeos’ best-in-class A2Areceptor antagonist, EOS100850, restores T-cell activation inhibited by adenosine. EOS100850 promotes anti-tumor efficacy in mouse tumor models in combination with several immune-checkpoint inhibitors, retains high potency in the presence of elevated intra-tumoral adenosine concentrations, and is non-brain penetrant. EOS100850 is currently being evaluated for safety and efficacy in preclinical models. About iTeos’ Human Anti-TIGIT Antibody (EOS884448) Tigit is an immunosuppressive receptor expressed on lymphoid cell populations. TIGIT expression increases in cancer patients and marks exhausted T cells. EOS884448 is an antagonist antibody against human TIGIT. Preclinical studies show its potency to restore T cell function and to preferentially deplete Treg cells in cancer patient material. ADCC/ADCP-enabling isotypes of a-TIGIT surrogate Ab show potent monotherapy efficacy in murine tumor models that correlates to increased T cell activation and reduced Treg infiltration of tumors. EOS884448 demonstrates classical human IgG pharmacokinetics profile and a good developability profile. EOS884448 is currently being evaluated for safety and efficacy in preclinical models. About iTeos Therapeutics iTeos Therapeutics is a privately-held, clinical-stage biopharmaceutical company dedicated to extending and improving the lives of cancer patients by designing and developing next generation immunotherapies. The Company is advancing EOS100850, an insurmountable and non-brain penetrant adenosine A2A receptor antagonist, into a Phase I trial in the second half of 2018. A second program for its human ADCC-enabling anti-TIGIT antibody (EOS884448) is expected to enter the clinic in 2019. The company is currently also evaluating its third program, EOS200271, a clinical-stage potent and selective IDO1 inhibitor. Based in Gosselies, Belgium, iTeos Therapeutics was founded out of the Ludwig Institute for Cancer Research (LICR) and the de Duve Institute in 2011, with funds from the LICR, the Walloon Region of Belgium and the European Fund for Economic and Regional Development (FEDER). For more information, please visit www.iteostherapeutics.com.   For further information, please contact: Michel Detheux, CEO iTeos Therapeutics info@iteostherapeutics.com   Amber Fennell, Mathew Neal, Sukaina Virji, Hendrik Thys Consilium Strategic Communications +44 203 709 5700 iteos@consilium-comms.com   Sarah McCabe Stern Investor Relations, Inc. + 1 212 362 1200 sarah@sternir.com

  • iTeos Therapeutics received the Gazelles 2018 award for Wallonia.
    Corporate

    iTeos Therapeutics received the Gazelles 2018 award for Wallonia.

    Gosselies, Belgium – March 21, 2018 - iTeos Therapeutics is pleased to have been awarded the Trends Gazelles 2018 award for Wallonia. Trends Gazelles Ambassadors are fast-growing companies that have a significant positive impact on the competitiveness and business dynamics of their region.

  • iTeos Therapeutics to Present at Upcoming March Conferences
    Corporate

    iTeos Therapeutics to Present at Upcoming March Conferences

    Gosselies, Belgium – March 5, 2018 – iTeos Therapeutics SA, a biotechnology company developing novel cancer immunotherapies, today announced that Michel Detheux, Ph.D., Chief Executive Officer of iTeos will present at two upcoming March conferences as follows: Cowen 38th Annual Health Care Conference on Monday, March 12, 2018 at 1:00 p.m. ET in Boston, MA. Oppenheimer 28th Annual Healthcare Conference on Tuesday, March 20, 2018 at 2:45 p.m. ET in New York, NY.  Additionally, Mohamed Ragab, M.D, Vice President of Corporate Development of iTeos, will be available for one-on-one meetings at BIO-EUROPE SPRING, the 12th Annual International Partnering Conference, on Monday, March 12, 2018 in Amsterdam, The Netherlands.   About iTeos Therapeutics Starting operations in 2012, iTeos Therapeutics is a clinical-stage biopharmaceutical company dedicated to extending and improving the lives of cancer patients by developing immunotherapies by design.  iTeos is developing EOS200271, a clinical-stage potent and selective IDO1 inhibitor with exceptional brain penetration. The company is also advancing EOS100850, an insurmountable and non-brain penetrant adenosine A2A receptor antagonist, into a Phase 1 trial in the second half of 2018; and a human ADCC-enabling anti-TIGIT antibody (EOS884448), representing an additional, third clinical entry in 2019. Based in Gosselies, Belgium, iTeos Therapeutics was founded and supported in part by investments from the Ludwig Institute Cancer Research (LICR), the Walloon Region of Belgium and the European Fund for Economic and Regional Development (FEDER). For more information, please visit www.iteostherapeutics.com.   For further information, please contact: Michel Detheux, CEO iTeos Therapeutics info@iteostherapeutics.com  Sarah McCabe and Carl Mauch Stern Investor Relations, Inc. + 1 212 362 1200 iTeos@sternir.com Amber Fennell, Mathew Neal, Hendrik Thys, Suki Virji Consilium Strategic Communications +44 203 709 5700 iteos@consilium-comms.com  

  • iTeos Therapeutics to Present New Preclinical Data from A2A Receptor Antagonist and Anti-TIGIT Antibody Programs at Molecular Medicine Tri-Conference
    A2a Inhibitor TIGIT

    iTeos Therapeutics to Present New Preclinical Data from A2A Receptor Antagonist and Anti-TIGIT Antibody Programs at Molecular Medicine Tri-Conference

    Two Phase 1 trials to start in 2018 for A2A receptor antagonist and IDO1 inhibitor Gosselies, Belgium – February 9, 2018 – iTeos Therapeutics SA, a biotechnology company developing novel cancer immunotherapies, today announces that it will present new data for its A2A antagonist and anti-TIGIT antibody programs in two oral presentations at the upcoming Molecular Medicine Tri-Conference 2018, taking place from February 11-16, 2018 in San Francisco, CA. “The preclinical data to be presented further demonstrate the potential of our insurmountable and non-brain penetrant A2A receptor antagonist in combination with immune checkpoints. With our anti-TIGIT antibody program, we saw anti-tumor efficacy and reactivation of T-cells in preclinical models which is encouraging for the potential of this product as a monotherapy, combining immune-modulation and antibody dependent, cell-mediated cytotoxicity,” said Michel Detheux, Ph.D., Chief Executive Officer of iTeos. “Our team's deep experience, along with the commitment and support of our investors, will allow us to pursue an aggressive development strategy for our best-in-class pipeline in the near-term. With full rights to our IDO1 inhibitor back in-house and the advancement of our A2A receptor antagonist program into the clinic in the third quarter, we will have two leading candidates in clinical trials in 2018.” Adenosine A2A Receptor Inhibitor (EOS100850): Best-in-class A2A receptor antagonist program currently being evaluated for safety and efficacy in preclinical models with a Phase I trial expected to begin in 2018. Presentation Title: EOS100850, a Best-in-Class, Insurmountable and Non-Brain Penetrant A2A Receptor Antagonist, Inhibits Adenosine-Mediated T Cell Suppression and Exhibits Anti-Tumor Activity Date & Time: Monday, February 12, 2018 Authors: Grégory Driessens Poster Number: 36 Key Takeaways: EOS100850 potently inhibits A2A receptor in T lymphocytes, at single digit nanomolar concentrations, independently of adenosine concentrations EOS100850 potently rescues Th1 cytokine production in human whole blood treated by A2A agonists, and increased CD8+ T cell cytotoxicity in a co-culture assay of effector CD8+ T cells and target cancer cells EOS100850 does not penetrate the brain In a mouse lymphoma model, combined with anti-PD-L1, EOS100850 showed significant enhancement of anti-tumoral activities compared with anti-PD-L1 alone Human Anti-TIGIT Antibody (EOS884448): Antagonist antibody against human TIGIT that demonstrates a classical human IgG pharmacokinetics profile. It is currently being evaluated for safety and efficacy in preclinical models with a Phase I trial expected to begin in 2019. Presentation Title: EOS884448 a novel ADCC-Enabling Antibody Targeting TIGIT Restores T Cell Effector Functions and Displays Anti-Tumor Efficacy Date & Time: Wednesday, February 14, 2018 Authors: Grégory Driessens Poster Number: 35 Key Takeaways: EOS884448 binds to human TIGIT and prevents binding of natural ligand at sub-nanomolar concentrations EOS884448 rescues activation of T cells from cancer patients PBMCs and TILs EOS884448 induces preferential depletion of Treg Surrogate mouse a-TIGIT shows potent antitumor efficacy that depends on Ab isotype IDO1 Inhibitor (EOS200271): Synthetic, small molecule inhibitor of indoleamine 2,3-dioxygenase (IDO1) to trigger immune-modulation in the tumor micro-environment. IDO1 inhibitors are one of the most promising immuno-oncology drugs currently in development. This asset is one of five IDO1 inhibitors in clinical development worldwide and EOS200271 is the only IDO1 inhibitor with excellent brain penetration confirmed in patients. EOS200271 is a unique asset and iTeos is evaluating its potential in different indications and combinations with the intention of resuming Phase 1 in 2018. A further update will be provided on clinical development plans in due course.   About iTeos’ Adenosine A2A Receptor Inhibitor (EOS100850) The adenosine A2A receptor is the main adenosine receptor expressed on immune cells, which promotes immune suppression, leading to tumor evasion. iTeos’ best-in-class A2A receptor antagonist, EOS100850, restores T-cell activation inhibited by adenosine. EOS100850 promotes anti-tumor efficacy in mouse tumor models in combination with several immune-checkpoint inhibitors, retains high potency in the presence of elevated intra-tumoral adenosine concentrations, and is non-brain penetrant. EOS100850 is currently being evaluated for safety and efficacy in preclinical models.   About iTeos’ Human Anti-TIGIT Antibody (EOS884448) TIGIT is an immunosuppressive receptor expressed on lymphoid cell populations. TIGIT expression increases in cancer patients and marks exhausted T cells. EOS884448 ­­is an antagonist antibody against human TIGIT. Preclinical studies show its potency to restore T cell function and to preferentially deplete Treg cells in cancer patient material. ADCC/ADCP-enabling isotypes of a-TIGIT surrogate Ab show potent monotherapy efficacy in murine tumor models that correlates to increased T cell activation and reduced Treg infiltration of tumors. EOS884448 demonstrates classical human IgG pharmacokinetics profile and a good developability profile. EOS884448 is currently being evaluated for safety and efficacy in preclinical models.   About iTeos’ IDO1 Inhibitor (EOS200271) EOS200271 is currently in Phase 1 clinical trials, which will be expanded in 2018. The drug candidate is a synthetic, small molecule inhibitor of indoleamine 2,3-dioxygenase (IDO1) that also inhibits IDO1 in the tumor micro-environment to trigger immune-modulation. EOS200271 is distinguished through its high level of brain penetration confirmed in clinical trials. EOS200271 has demonstrated anti-tumor activity in multiple preclinical tumor models in monotherapy and in combination with immune checkpoint inhibitors. EOS200271 was originally licensed from iTeos to Pfizer in December 2014, and was returned to iTeos in 2017.   About iTeos Therapeutics Starting operations in 2012, iTeos Therapeutics is a clinical-stage biopharmaceutical company dedicated to extending and improving the lives of cancer patients by developing immunotherapies by design.  iTeos is developing EOS200271, a clinical-stage potent and selective IDO1 inhibitor with exceptional brain penetration. The company is also advancing EOS100850, an insurmountable and non-brain penetrant adenosine A2A receptor antagonist, into a Phase 1 trial in the second half of 2018; and a human ADCC-enabling anti-TIGIT antibody (EOS884448), representing an additional, third clinical entry in 2019. Based in Gosselies, Belgium, iTeos Therapeutics was founded and supported in part by investments from the Ludwig Institute Cancer Research (LICR), the Walloon Region of Belgium and the European Fund for Economic and Regional Development (FEDER). For more information, please visit www.iteostherapeutics.com.   For further information, please contact: Michel Detheux, CEO iTeos Therapeutics info@iteostherapeutics.com Amber Fennell, Mathew Neal, Hendrik Thys, Suki Virji Consilium Strategic Communications +44 203 709 5700 iteos@consilium-comms.com Sarah McCabe Stern Investor Relations, Inc. + 1 212 362 1200 sarah@sternir.com